The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | CAR T-cell immunotherapy: current status and perspectives
In this video, Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, shares his views on the current status of CAR T-cell therapy. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Prof. Nagler mentions the especially promising results of the therapy in acute lymphoblastic leukemia (ALL) and lymphoma patients. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
